Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia.

Authors

Longzhen Cui
Yan Liu
Yifan Pang, Beaumont Health Fellow
Tingting Qian
Liang Quan
Zhiheng Cheng
Yifeng Dai
Xu Ye
Ying Pang
Jinlong Shi
Xiaoyan Ke
Depei Wu
Lin Fu

Document Type

Article

Publication Date

2-1-2020

Publication Title

Cancer Gene Therapy

Abstract

Relapsed and refractory acute myeloid leukemia (R/R AML) has complicated pathogenesis. Its treatment is complicated, and the prognosis is poor. So far, there is no consensus on what is the optimal treatment strategy. With the deepening of research, new chemotherapy regimens, new small molecule inhibitors, and immunotherapy have been increasingly applied to clinical trials, providing more possibilities for the treatment of R/R AML. The most effective treatment for patients who achieve complete remission after recurrence is still sequential conditioning therapy followed by allogeneic hematopoietic cell transplantation. Finding the best combination of treatments is still an important goal for the future.

Volume

27

Issue

1-2

First Page

1

Last Page

14

Recommended Citation

Cui L, Liu Y, Pang Y, Qian T, Quan L, Cheng Z, Dai Y, Ye X, Pang Y, Shi J, Ke X, Wu D, Fu L. Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia. Cancer Gene Ther. 2020 Feb;27(1-2):1-14. doi: 10.1038/s41417-019-0119-5. Epub 2019 Jul 11. PMID: 31292516.

DOI

10.1038/s41417-019-0119-5

ISSN

1476-5500

PubMed ID

31292516